Company

Company
Leadership

Leadership

Founder & CEO
NA Vaccine Institute
Adjunct Professor, POSTECH
"A pioneering RNA biologist and biotech entrepreneur
shaping the future of TLR3-based immunotherapy."

Dongho Kim / Ph.D.

Dr. Dongho Kim is a biotech entrepreneur and
expert in RNA biology and immunology,
with 20+ years across academia and industry.
He has founded and led multiple companies in RNA therapeutics
and immune-modulating technologies, and is currently advancing
a next-generation TLR3 agonist–based immunotherapy platform
for cancer and infectious diseases.

CORE EXPERTISE

  • RNA biology & therapeutics (siRNA, Dicer mechanisms)

  • Innate immunity and TLR3 signaling

  • Vaccine adjuvant and delivery platforms

  • Cancer immunotherapy (NK activation, immune priming)

CURRENT FOCUS — NA Vaccine Institute (2018–Present)

Developing formulated TLR3 agonist platforms for in vivo immune activation for

  • Cancer immunotherapy

  • Therapeutic vaccines

  • In vivo NK cell activation

PRIOR LEADERSHIP Experience

  • Genolution Pharmaceuticals (Founder & CEO/CTO, 2006–2017)

  • Early pioneer in RNA-based therapeutics

  • Built foundational capabilities in RNA production and platform development

ACADEMIC BACKGROUND

  • Ph.D. in Microbiology — University of Texas at Austin

  • Postdoctoral Research — Beckman Research Institute, City of Hope

SCIENTIFIC CONTRIBUTIONS

  • Pioneering work in RNAi biology and Dicer-mediated processing

  • Development of defined TLR3 agonists (Nexavant)

  • Robust immune activation & anti-cancer efficacy in preclinical models

Executive Vice President
COO / CTO
NA Vaccine Institute
"A biological science expert leading biopharmaceutical
innovation with 20+ years of industry & academic expertise."

Seung Bum Hong / Ph.D.

CORE COMPETENCIES

Overseeing the full development cycle of first-in-class immunomodulators

  • CMC: Chemistry, Manufacturing & Controls optimization

  • Clinical: Managing development programs for next-generation pipelines

  • Preclinical: Planning of safety and efficacy studies

PROFESSIONAL EXPERIENCE

  • Current) Executive Vice President (COO/CTO), NA Vaccine Institute

  • Former) Team Leader, Validation & Preclinical Studies, ISU ABXIS Co., Ltd.

  • Former) Researcher, National Cancer Institute (NCI) & Univ. of Pennsylvania, USA

  • Former) Senior Researcher, Samsung Biomedical Research Institute

KEY ACHIEVEMENTS

  • Clinical Success: Multiple Phase 1 projects - anti-ErbB3 mAb & Coagulation Factor IX

  • Research: Rare kidney cancer & Birt-Hogg-Dube (BHD) syndrome contributions

EDUCATION

  • Ph.D. M.S., B.S. in Biological Sciences - KAIST

  • Korea Advanced Institute of Science and Technology

  • Numerous publications in Oncology, Immunology & Pharmacokinetics (PK)

Head of Research
NA Vaccine Institute
"Infectious Disease & Immuno-oncology Expert
with Veterinary R&D Expertise."

Seung Bin Cha / DVM, Ph.D.

CORE EXPERTISE

  • Infectious disease vaccine development (Influenza, TB, COVID-19)

  • Strategic R&D planning for immuno-oncology

  • Veterinary microbiology and preclinical research

PROFESSIONAL EXPERIENCE

  • Current) Head of Research, NA Vaccine Institute

  • Former) R&D Program Lead, NA Vaccine Institute

  • Former) Senior Research Scientist, QURATIS

  • Former) Research Professor, Institute for Immunology & Immunological

  • Diseases, Yonsei University College of Medicine

  • Former) Senior Researcher, Korea National Institute of Health (KNIH)

EDUCATION

  • Ph.D. in Veterinary Microbiology — Seoul National University

  • DVM (Doctor of Veterinary Medicine) — Chungnam National University

  • Tae-Rim Yun

    CFO

    • Former) SK Planet Investment Management Team Leader

    • Former) SK Telecom Business Management Team Leader

    • Global MBA, Sungkyunkwan University

    • Graduated from Sungkyunkwan University, Department of Commerce

  • Kyung-Sik Jeon

    IP/Legal Department (Patent Attorney)

    • Former) Kolon Industries Intellectual Property Team Leader

    • Former) Member patent attorney at Yumi Patent Firm

    • Former) Partner patent attorney at Halla Patent Firm

    • Master's course in Biomolecular and Genetic Engineering, Graduate School of Life and Environmental Sciences, Korea University

    • Graduated from University of Seoul, Department of Life Sciences

  • Yo-Han Kim

    Non-Executive Director

    • Current) DSC Investment Executive Director

    • Former) IMM Investment

    • Former) Hanmi Pharmaceutical

    • Seoul National University Graduate School, Master of Pharmaceutical Sciences

    • Graduated from Seoul National University, Department of Pharmacy